Spirotryprostatin A | 182234-25-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Spirotryprostatin A
• 英文别名: (3S,5S,6S,9S)-6'-methoxy-6-(2-methylprop-1-enyl)spiro[1,7-diazatricyclo[7.3.0.03,7]dodecane-5,3'-1H-indole]-2,2',8-trione
• CAS: 182234-25-9
• 化学式: C₂₂H₂₅N₃O₄
• 分子量: 395.458
• InChiKey: MQJKGSIAJNXSCM-ORGXJRBJSA-N

物化性质

• 沸点：
  658.9±55.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  79
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  碘甲烷 、 Spirotryprostatin A 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 0.67h， 以0.9 mg的产率得到N-methylspirotryprostatin A
  参考文献：
  名称：

  Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi

  摘要：

  Human African trypanosomiasis (HAT, commonly known as African sleeping sickness) is categorized as a neglected disease, as it afflicts >50,000 people annually in sub-saharan Africa, and there are few formal programs in the world focused on drug discovery approaches for this disease. In this study, we examined the crude extracts of two fungal strains (Aspergillus fumigatus and Nectria inventa) isolated from deep water sediment which provided >99% growth inhibition at 1 mu g/mL of Trypanosoma brucei, the causative parasite of HAT. A collection of fifteen natural products was supplemented with six semi-synthetic derivatives and one commercially available compound. Twelve of the compounds, each containing a diketopiperazine core, showed excellent activity against T. brucei (IC50 = 0.002-40 mu M), with selectivity over mammalian cells as great as 20-fold. The trypanocidal diketopiperazines were also tested against two cysteine protease targets Rhodesain and TbCatB, where five compounds showed inhibition activity at concentrations less than 20 mu M. A preliminary activity pattern is described and analyzed. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.02.034
• 作为产物：
  描述：

  2-氨基-3-(6-甲氧基-1H-吲哚-3-基)丙酸甲酯 在 sodium periodate 、 N-溴代丁二酰亚胺(NBS) 、 rhodium(III) chloride 、 4 A molecular sieve 、 水 、 氯化铵 、 溶剂黄146 、 三乙胺 、 三氟乙酸 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， 反应 7.0h， 生成 Spirotryprostatin A
  参考文献：
  名称：

  The Total Synthesis of Spirotryprostatin A

  摘要：

  Eight concise steps suffice for the first total synthesis of the title compound 1, which inhibits the transitions from the G2 and M phases into the next phases of the cell cycle. Key steps in the synthesis are a stereocontrolled oxidative rearrangement of an indole to form the chiral spiroindolinone nucleus and a regioselecitve sulfoxide elimination.

  DOI：

  10.1002/(sici)1521-3773(19980504)37:8<1138::aid-anie1138>3.0.co;2-n

文献信息

• Total Synthesis of Spirotryprostatins through Organomediated Intramolecular Umpolung Cyclization
  作者：Yong-Kai Xi、Hongbin Zhang、Rui-Xi Li、Shi-Yuan Kang、Jin Li、Yan Li

  DOI：10.1002/chem.201806411

  日期：2019.2.26

  reports a new method for the synthesis of biologically important DKP scaffolds based on an intramolecular nucleophilic α‐addition of general amides towards an alkynamide system. The utility of this umpolung cyclization mediated by trimethyl phosphine and l‐glutamic acid is highlighted by its application to the concise total syntheses of 6‐methoxyspirotryprostatin B (the first total synthesis), spirotryprostatin A

  环二肽2,5-二酮哌嗪（DKP）是药物和天然生物碱中的特权结构单元。这项工作报告了一种新的合成重要生物学DKP支架的方法，该方法基于一般酰胺的分子内亲核α加成到炔酰胺系统。由三甲基膦和l-谷氨酸介导的这种蛋白环环化的实用性通过将其应用于简明的6-甲氧基spirotryprostatin B（首次合成），spirotryprostatin A和spirotryprostatin B的简明总合成中而得到了应用。
• Total Synthesis of Spirotryprostatin A, Leading to the Discovery of Some Biologically Promising Analogues
  作者：Scott Edmondson、Samuel J. Danishefsky、Laura Sepp-Lorenzino、Neal Rosen

  DOI：10.1021/ja983788i

  日期：1999.3.1

  The total synthesis of the title compound has been accomplished. A key step involves the oxidative rearrangement of the β-carboline derivative to an oxindole via the action of N-bromosuccinimide. From this point, a diketopiperazine was introduced. A thiophenyl group served as a precursor of the isopropylidene function. Implementation of the same sort of chemistry starting with a methoxytryptophan derivative

  标题化合物的全合成已经完成。一个关键步骤涉及通过 N-溴代琥珀酰亚胺的作用将 β-咔啉衍生物氧化重排为羟吲哚。从这一点开始，引入了二酮哌嗪。噻吩基用作异亚丙基官能团的前体。从甲氧基色氨酸衍生物开始实施相同类型的化学反应导致母体结构。此外，已经表明，螺环前列腺素 A 的难以接近的异亚丙基侧链对于生物活性不是必需的。此外，三种缺乏二酮哌嗪系统的类似物被证明作为细胞周期抑制剂非常活跃。
• Spirooxindole-pyrrolothiazole heterocyclic hybrids
  申请人：KING SAUD UNIVERSITY

  公开号：US10590147B1

  公开（公告）日：2020-03-17

  The spirooxindole-pyrrolothiazole heterocyclic hybrids are compounds having the formula: wherein R is hydrogen and R′ is fluorine (compound 6a) or R is fluorine and R′ is hydrogen (compound 6b). The hybrids may be obtained using a chemical synthesis process involving 1,3-dipolar cycloaddition of 3,5-bis(4/2-fluoro-benzylidene) piperidin-4-ones with isatin and 4-thiazolidinecarboxylic acid in a suitable solvent, preferably 1-butyl-3-methyl-imidazolium bromide (“[bmim]Br”), and preferably under microwave irradiation. Both of these new hybrids demonstrate antimicrobial activity against both gram positive and gram negative drug resistant and non-resistant bacterial pathogens, although compound 6a exhibits more potent antibacterial activity than compound 6b.

  螺环氧吲哚-吡咯噻唑杂环混合物是具有以下化学式的化合物：其中R为氢，R′为氟（化合物6a），或者R为氟，R′为氢（化合物6b）。这些杂合物可以通过化学合成过程获得，涉及3,5-双(4/2-氟苄亚甲基)哌啶-4-酮与吲哚酮和4-噻唑烷羧酸进行1,3-偶极环加成，在适当溶剂中，最好是1-丁基-3-甲基-咪唑溴化物（“[bmim]Br”），并最好在微波辐射下进行。这两种新的杂合物对革兰氏阳性和革兰氏阴性耐药和非耐药细菌病原体均表现出抗菌活性，尽管化合物6a表现出比化合物6b更强的抗菌活性。
• SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF
  申请人：Wang Shaomeng

  公开号：US20120101092A1

  公开（公告）日：2012-04-26

  The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).

  本发明涉及小分子，其作为p53和MDM2相互作用的抑制剂。本发明还涉及使用这些化合物来抑制细胞生长，诱导细胞死亡，诱导细胞周期停滞和/或使细胞对其他药物更敏感。
• PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN
  申请人：Wang Shaomeng

  公开号：US20130030173A1

  公开（公告）日：2013-01-31

  The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).

  本发明涉及作为p53和MDM2相互作用抑制剂的小分子。本发明还涉及使用这些化合物来抑制细胞生长，诱导细胞死亡，诱导细胞周期阻滞和/或使细胞对其他药物敏感。